Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-peptidase IV Beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction
Overview
Authors
Affiliations
The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes. Surprisingly, CD26/DPP IV not only removed the expected Gly1-Pro2 dipeptide from the NH2 terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr3-Gly4 dipeptide, generating MDC(5-69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP IV was confirmed on the synthetic peptides GPYGANMED (MDC(1-9)) and YGANMED (MDC(3-9)). Compared with intact MDC(1-69), CD26/DPP IV-processed MDC(5-69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca2+ through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca2+-responses in CCR4 transfectants. However, MDC(5-69) remained equally chemotactic as intact MDC(1-69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5-69) retained its binding properties to monocytes and its anti-HIV-1 activity. Thus, NH2-terminal truncation of MDC by CD26/DPP IV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation.
Sun H, Qi X Discov Oncol. 2022; 13(1):70.
PMID: 35933633 PMC: 9357599. DOI: 10.1007/s12672-022-00536-8.
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.
Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K Diabetes Metab Syndr Obes. 2022; 15:1845-1864.
PMID: 35733643 PMC: 9208633. DOI: 10.2147/DMSO.S369712.
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
Huang J, Liu X, Wei Y, Li X, Gao S, Dong L Front Immunol. 2022; 13:830863.
PMID: 35309368 PMC: 8931313. DOI: 10.3389/fimmu.2022.830863.
CCR4 as a Therapeutic Target for Cancer Immunotherapy.
Yoshie O Cancers (Basel). 2021; 13(21).
PMID: 34771703 PMC: 8583476. DOI: 10.3390/cancers13215542.
The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer.
De Zutter A, Van Damme J, Struyf S Cancers (Basel). 2021; 13(17).
PMID: 34503058 PMC: 8428238. DOI: 10.3390/cancers13174247.